CN1039126C - 抗塔基奎宁的三环化合物,及含该化合物的药物组合物 - Google Patents

抗塔基奎宁的三环化合物,及含该化合物的药物组合物 Download PDF

Info

Publication number
CN1039126C
CN1039126C CN93104453A CN93104453A CN1039126C CN 1039126 C CN1039126 C CN 1039126C CN 93104453 A CN93104453 A CN 93104453A CN 93104453 A CN93104453 A CN 93104453A CN 1039126 C CN1039126 C CN 1039126C
Authority
CN
China
Prior art keywords
formula
substituents
compound shown
nhco
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93104453A
Other languages
English (en)
Chinese (zh)
Other versions
CN1080916A (zh
Inventor
V·帕沃尼
A·劳巴迪
C·匹道尼
C·A·马基
L·夸塔拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guidaoti Laboratory Co ltd
Malus Biopharmaceutical Research Co ltd
A Menarini Industrie Farmaceutiche Riunite SRL
Original Assignee
Guidaoti Laboratory Co ltd
Malus Biopharmaceutical Research Co ltd
A Menarini Industrie Farmaceutiche Riunite SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guidaoti Laboratory Co ltd, Malus Biopharmaceutical Research Co ltd, A Menarini Industrie Farmaceutiche Riunite SRL filed Critical Guidaoti Laboratory Co ltd
Publication of CN1080916A publication Critical patent/CN1080916A/zh
Application granted granted Critical
Publication of CN1039126C publication Critical patent/CN1039126C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN93104453A 1992-04-15 1993-04-14 抗塔基奎宁的三环化合物,及含该化合物的药物组合物 Expired - Fee Related CN1039126C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI920089A IT1262902B (it) 1992-04-15 1992-04-15 Composti triciclici antagonisti delle tachichinine, loro preparazione e loro uso in composizioni farmaceutiche.
ITFI92A000089 1992-04-15

Publications (2)

Publication Number Publication Date
CN1080916A CN1080916A (zh) 1994-01-19
CN1039126C true CN1039126C (zh) 1998-07-15

Family

ID=11350056

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93104453A Expired - Fee Related CN1039126C (zh) 1992-04-15 1993-04-14 抗塔基奎宁的三环化合物,及含该化合物的药物组合物

Country Status (28)

Country Link
EP (1) EP0636146B1 (enExample)
JP (1) JPH08500331A (enExample)
KR (1) KR950700935A (enExample)
CN (1) CN1039126C (enExample)
AT (1) ATE156135T1 (enExample)
AU (1) AU671118B2 (enExample)
BG (1) BG99110A (enExample)
BR (1) BR9306248A (enExample)
CA (1) CA2118253A1 (enExample)
CZ (1) CZ254294A3 (enExample)
DE (1) DE69312698T2 (enExample)
DK (1) DK0636146T3 (enExample)
ES (1) ES2105265T3 (enExample)
FI (1) FI944838A7 (enExample)
GR (1) GR3024348T3 (enExample)
HR (1) HRP930814A2 (enExample)
HU (1) HUT70189A (enExample)
IL (1) IL105381A (enExample)
IT (1) IT1262902B (enExample)
MX (1) MX9302161A (enExample)
NO (1) NO943861L (enExample)
NZ (1) NZ251969A (enExample)
RO (1) RO112872B1 (enExample)
RU (1) RU94045890A (enExample)
SK (1) SK124294A3 (enExample)
TW (1) TW234718B (enExample)
WO (1) WO1993021227A1 (enExample)
ZA (1) ZA932644B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277835B1 (it) * 1995-03-13 1997-11-12 Menarini Farma Ind Composti biciclici, loro preparazione ed uso in composizioni farmaceutiche
IT1283171B1 (it) * 1996-03-01 1998-04-16 Interdipartimentale Di Ricerca Composti solubili antagonisti delle tachichinine loro preparazione e loro uso in composizioni farmaceutiche
IT1291776B1 (it) 1997-02-07 1999-01-21 Menarini Ricerche Spa Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
EP1297826A1 (en) * 2001-09-27 2003-04-02 Menarini Ricerche S.p.A. Nasal pharmaceutical compositions containing a NK-2 antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216529A (en) * 1988-03-25 1989-10-11 Merck Sharp & Dohme Peptides useful as tachykinin antagonists
DE3915361A1 (de) * 1989-05-11 1990-11-15 Merck Patent Gmbh Cyclopeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216529A (en) * 1988-03-25 1989-10-11 Merck Sharp & Dohme Peptides useful as tachykinin antagonists
DE3915361A1 (de) * 1989-05-11 1990-11-15 Merck Patent Gmbh Cyclopeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.A.VOL116,NO16246J;C.A.VOL117,NO1044168 *

Also Published As

Publication number Publication date
ITFI920089A0 (it) 1992-04-15
AU671118B2 (en) 1996-08-15
SK124294A3 (en) 1995-07-11
ES2105265T3 (es) 1997-10-16
WO1993021227A1 (en) 1993-10-28
CN1080916A (zh) 1994-01-19
TW234718B (enExample) 1994-11-21
FI944838L (fi) 1994-10-14
GR3024348T3 (en) 1997-11-28
MX9302161A (es) 1994-05-31
RU94045890A (ru) 1996-09-10
RO112872B1 (ro) 1998-01-30
CZ254294A3 (en) 1995-07-12
IT1262902B (it) 1996-07-22
DE69312698T2 (de) 1997-12-04
AU4039593A (en) 1993-11-18
ZA932644B (en) 1993-10-22
NO943861D0 (no) 1994-10-13
HU9402977D0 (en) 1995-02-28
NZ251969A (en) 1997-12-19
IL105381A (en) 1998-02-22
HUT70189A (en) 1995-09-28
FI944838A0 (fi) 1994-10-14
DK0636146T3 (da) 1998-02-23
EP0636146B1 (en) 1997-07-30
DE69312698D1 (de) 1997-09-04
EP0636146A1 (en) 1995-02-01
ATE156135T1 (de) 1997-08-15
BG99110A (bg) 1995-09-29
FI944838A7 (fi) 1994-10-14
ITFI920089A1 (it) 1993-10-15
KR950700935A (ko) 1995-02-20
JPH08500331A (ja) 1996-01-16
HRP930814A2 (en) 1996-12-31
NO943861L (no) 1994-10-13
CA2118253A1 (en) 1993-10-28
BR9306248A (pt) 1998-06-23

Similar Documents

Publication Publication Date Title
KR101904808B1 (ko) 데가렐릭스 및 이의 중간 화합물의 제조 방법
KR20010022924A (ko) 페네틸아민 유도체
CN1161374C (zh) 环肽
RS55457B1 (sr) Postupak za proizvodnju degareliksa i njegovih intermedijara
CN1185251C (zh) 具有改进溶解性能的新的lhrh－拮抗剂
AU664855B2 (en) Lanthionine bridged peptides
CN1039126C (zh) 抗塔基奎宁的三环化合物,及含该化合物的药物组合物
CN1462277A (zh) 包含止痛肽的药物组合物
US5731285A (en) Tachiquinine antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
AU696528B2 (en) Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition
CN1087283C (zh) 作用改善的新lh－rh拮抗剂
CN102858779A (zh) 环状四肽及其治疗性应用
CN1100787C (zh) 新型血吸虫疫苗肽
CN1100788C (zh) 新型血吸虫疫苗肽
CN1532206A (zh) 胸腺素α1的活性片段及其聚乙二醇化衍生物
EP4240395A1 (en) Antiviral structurally-stabilized ebolavirus peptides and uses thereof
EP0606222A1 (en) Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof
RU2020101972A (ru) Модифицированная l-аспарагиназа
JPWO1995000546A1 (ja) エンドセリン拮抗ペプチド類
HK1016999B (en) Novel lh-rh antagonists having improved action

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee